Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 17/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 17/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 17/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 17/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 17/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 17/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 17/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 17/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 17/20 | 0.63 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | FABP1 | P07148 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289611 | 0.82 | HDAC2 (0.62) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL4166775 | 0.81 | HDAC1 (0.74) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL4171051 | 0.80 | HDAC1 (0.60) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL4020428 | 0.80 | HDAC2 (0.60) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL4025219 | 0.80 | HDAC1 (0.72) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL4183793 | 0.80 | HDAC1 (0.72) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL5353081 | 0.80 | HDAC2 (0.57) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL4175980 | 0.79 | HDAC2 (0.58) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL6356036 | 0.79 | HDAC3 (0.59) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL4019056 | 0.79 | HDAC3 (0.70) | HDAC1HDAC3HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250784-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-11-10 | — | — | US | disclosed |
| US-20050197336-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197336-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | HDAC1 1/4885HDAC3 6/4885HDAC4 11/4885 |
| US-20050250784-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | HDAC1 1/4885HDAC3 6/4885HDAC4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.